On July 2, 2026, the Social Security Administration (SSA) published a long-awaited final rule comprehensively revising the medical criteria used to evaluate cardiovascular disorders under the Listing of Impairments. The new regulations, published at 20 C.F.R. Parts 404 and 416, become effective October 30, 2026, and will apply to all claims pending on or after that date, including cases remanded by federal courts after the effective date.
The revisions represent the first major overhaul of the cardiovascular listings in several years and are intended to reflect advances in medical science, evolving treatment options, and SSA’s adjudicative experience. According to SSA, the changes also incorporate feedback received through the rulemaking process from medical experts, disability advocates, and the public.
Perhaps the most notable aspect of the final rule is the addition of several entirely new listings. SSA has created Listing 4.07 for Aortic Valvular Disease, 4.08 for Cardiomyopathy, and 4.16/104.16 for Cardiac Allograft Vasculopathy, recognizing these conditions as distinct impairments that warrant separate listing criteria rather than requiring claimants to fit within more general cardiovascular provisions. SSA explained that these additions better address serious cardiovascular conditions that previously lacked listing-specific guidance.
The agency also substantially revised the introductory text for both the adult (Section 4.00) and childhood (Section 104.00) cardiovascular listings. The revisions modernize medical terminology, clarify how SSA evaluates cardiovascular disorders, and place greater emphasis on objective medical evidence, response to prescribed treatment, and resulting functional limitations. SSA updated definitions for key terms, including “persistent,” and clarified the role of agency medical consultants in evaluating complex cardiovascular evidence.
In addition to creating new listings, SSA reorganized and updated existing criteria for chronic heart failure, ischemic heart disease, recurrent arrhythmias, congenital heart disease, aneurysms, peripheral arterial disease, and chronic venous insufficiency. Many of the revisions reflect advances in diagnostic imaging, current treatment protocols, and contemporary cardiology practice. Rather than relying on outdated terminology or testing methods, the revised listings incorporate modern diagnostic approaches and recognize improvements in long-term survival that have changed how many cardiovascular diseases present in disability claims.
Importantly for representatives, the effective date is delayed until October 30, 2026, to allow SSA time to update its systems and provide training to adjudicators. Until that date, adjudicators will continue applying the current cardiovascular listings. Beginning October 30, however, the revised rules will govern new applications, pending administrative claims, continuing disability reviews where applicable, and any claim decided after the effective date. SSA also notes that if a federal court remands a case after October 30, 2026, the agency will apply the new cardiovascular listings on remand, regardless of when the original application was filed.
For advocates, the revised listings present both opportunities and challenges. The addition of listing-specific criteria for cardiomyopathy, aortic valvular disease, and cardiac allograft vasculopathy may provide clearer pathways to meeting a listing for claimants with these severe conditions. At the same time, representatives should carefully review the revised medical criteria and updated terminology, as evidentiary requirements have changed in several areas. Medical records that may have satisfied prior listing language should not be assumed to meet the revised criteria without a careful comparison to the new regulations.
As SSA begins training adjudicators on the revised listings, disability representatives should likewise familiarize themselves with the new criteria before the October implementation date.
